Jan 10, 2020
BW Therapeutics Announces Opening Of Series A Round And Strategic Partnering Initiatives
Nov 21, 2019
Catalent to Supply BeiGene's BTK Inhibitor BRUKINSA(TM) (zanubrutinib)
Sep 27, 2019
Health Canada approves Tecentriq® in combination with chemotherapy (nab-paclitaxel) as first immunotherapy treatment for aggressive form of breast cancer(1)
Jul 01, 2019
Boston Biomedical, Inc. Announces Update on Phase 3 CanStem111P Study of Napabucasin in Patients with Metastatic Pancreatic Cancer Following Interim Analysis
Feb 04, 2019
BioLineRx Receives Orphan Drug Designation From the FDA for its Lead Therapeutic Candidate BL-8040 for the Treatment of Pancreatic Cancer
Jan 18, 2019
AbbVie Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA®) in Metastatic Pancreatic Cancer
Aug 09, 2018
BeiGene Initiates New Phase 3 Trial of Anti-PD-1 Antibody Tislelizumab Combined with Chemotherapy as First-line Treatment for Patients with Advanced Squamous Non-Small Cell Lung Cancer in China
Jun 25, 2018
Merrimack Announces Top-Line Results from Randomized Phase 2 Trial of MM-141 in Front-Line Metastatic Pancreatic Cancer
Jun 01, 2018
Boston Biomedical, Inc. Highlights Presentations on Investigational Agents Napabucasin and DSP-7888 (ombipepimut-S*) at ASCO 2018
May 17, 2018
Boston Biomedical, Inc. Announces Presentations for Investigational Agents Napabucasin and DSP-7888 (ombipepimut-S*) to be Featured at ASCO 2018
Apr 20, 2018
Global $200 Billion Opportunity for Nanoparticle Drug Delivery Market by 2024 - Size, Current Trends, and Dynamics
Dec 20, 2017
MabVax Therapeutics Announces Completion of Enrollment and Initial Patient Dosing in an Expanded Cohort of the Phase 1 Trial Evaluating MVT-5873 in Combination with First-Line Chemotherapy
Jun 28, 2017
Halozyme Phase 2 Data In Advanced Pancreas Cancer Presented At European Society For Medical Oncology Symposium
Jun 04, 2017
Halozyme Phase 2 Data In Advanced Pancreas Cancer Featured In An Oral Presentation At ASCO
Jun 03, 2017
Boston Biomedical Presents Data Suggesting Anti-Cancer Activity of Investigational Stemness Inhibitor Napabucasin in Seven Tumor Types at ASCO 2017